Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC

TOP - August 2018, Vol 11, No 2 - Immunotherapy
Charles Bankhead


The combination of an immunotherapy and a targeted therapy demonstrated modest clinical activity but achieved durable responses in patients with me­tastatic colorectal cancer (mCRC) and had longer survival compared with historical standards, initial data from an ongoing trial presented at the 2018 Gastrointestinal Cancers Symposium showed.

Among the 84 patients, 7 had partial responses with the combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic). The median duration of response was 14.3 months.

The median progression-free survival (PFS) was 1.9 months, and median overall survival (OS) was 9.8 months. And 66% of patients were alive at 6 months, with almost 50% at 12 months, reported Johanna C. Bendell, MD, Director, GI Cancer Research Program, Sarah Cannon Research Institute/Tennessee Oncology, Nashville.

“The combination of atezolizu­mab and cobimetinib was well-tolerated in heavily pretreated patients with locally advanced or metastatic colorectal cancer,” she said. “The 12-month overall survival compared favorably with the 12-month overall survival of 24% observed with regorafenib. Durable responses were observed regardless of KRAS status and in patients with microsatellite stable tumors, patient populations with a high unmet medical need.”

Patients with chemotherapy-refractory, locally advanced or mCRC typically have poor survival of 6 to 7 months. Single-agent PD-1/PD-L1 inhibitors have demonstrated minimal activity in microsatellite stable (MSS) mCRC.

“Microsatellite stable metastatic colo­rectal cancer is characterized by lower tumor mutational burden that results in fewer neoantigens compared with microsatellite instability [MSI]-high tumors,” Dr Bendell noted.

Preclinical studies suggested potential therapeutic synergy with the combination of atezolizumab and cobimetinib. To evaluate the combination, investigators conducted a 2-stage, phase 1b dose-escalation/cohort-­expansion trial involving patients with several types of advanced solid tumors, including chemo­therapy-­refractory locally advanced or mCRC.

During the first stage, patients received atezolizumab 800 mg with cobimetinib at doses of 20 mg to 60 mg. During the expansion stage, all patients received atezolizumab 800 mg and cobimetinib 60 mg. The primary end points were safety and tolerability of the combination. Secondary end points included investigator-assessed objective response, PFS, and OS.

Patients were unselected for PD-L1 expression status, and MSI status was locally reported and centrally confirmed by next-generation sequencing–based scoring.

The study population included 84 patients with mCRC. They had a median age of 56.5 years, 79% had received ≥5 previous systemic therapies, 68% had KRAS mutations, 57% had low PD-L1 expression, and 50% had MSS tumors.

The majority of patients had treatment-related adverse events. The incidence of grade 3/4 adverse events was 38%, and serious adverse events occurred in 45% of patients (12% of events were judged to be treatment- related). Adverse events leading to withdrawal of treatment was 24%, which was more common with cobimetinib (24%) than with atezolizumab (13%).

The combination therapy resulted in an objective response rate of 8% and an additional 23% of patients had stable disease for ≥6 weeks, with a disease control rate of 31%. The overall median PFS was 2.5 months in patients with MSS tumors, 2.0 months in patients with KRAS mutations, and 1.8 months in those with KRAS wild type.

The median OS ranged from 9.5 months for patients with KRAS mutations to 10.0 months for those with KRAS wild type, to 13.0 months for patients with MSS tumors. The 6- and 12-month OS was 65% and 43%, respectively. The highest survival rate was in the subgroup of patients with MSS tumors (71% at 6 months vs 51% at 12 months).

“The combination of atezolizumab and cobimetinib represents the first potential immune-modifying combination for patients with microsatellite stable metastatic colorectal cancer,” Dr Ben­dell said. “Data from the confirmatory phase 3 study, known as IMblaze370, are anticipated later this year.”

Related Items
Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer
JHOP Web Exclusives published on December 12, 2018 in Immunotherapy
Building on the Successes of Cancer Immunotherapy
Charles Bankhead
JHOP Web Exclusives published on November 26, 2018 in Immunotherapy
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
TOP Web Exclusives published on October 9, 2018 in Immunotherapy, Multiple Myeloma
Immune Checkpoint Inhibitors: Test Your Knowledge Level
Eileen Koutnik-Fotopoulos
TOP Web Exclusives published on September 11, 2018 in Immunotherapy
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
JHOP Web Exclusives published on August 6, 2018 in Immunotherapy
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018
Last modified: November 6, 2018